Dentate gyrus granule cells are hippocampal excitatory neurons critically affected in Lafora disease (LD), a rare autosomal recessive progressive myoclonus epilepsy characterized by intracellular polyglucosan inclusion bodies (Lafora bodies). These neurons play essential roles in pattern separation, adult neurogenesis, and spatial memory encoding—functions progressively impaired as Lafora bodies accumulate within their cytoplasm.
Lafora disease represents a unique intersection of glycogen metabolism disorders and neurodegeneration, offering insights into broader mechanisms of protein/glycogen aggregation relevant to Alzheimer's disease, Parkinson's disease, and other tauopathies.[1][2]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000120 | granule cell |
Dentate granule cells reside in the granule cell layer of the dentate gyrus, the "gateway" to the hippocampal formation. Their densely packed somata extend dendrites into the molecular layer, receiving perforant path input from the entorhinal cortex, and project axons (mossy fibers) to CA3 pyramidal cells.[3]
| Property | Description |
|---|---|
| Location | Dentate gyrus granule cell layer |
| Projection | Mossy fibers to CA3 |
| Input | Perforant path (layer II entorhinal) |
| Neurotransmitter | Glutamate |
| Molecular markers | Prox1, Calbindin, NeuN |
The dentate gyrus performs pattern separation—transforming similar input patterns into distinct output representations. This computational function depends on:
Dentate granule cells are unique among hippocampal neurons in their capacity for adult neurogenesis. Neural stem cells in the subgranular zone continuously generate new granule cells throughout life, with newborn neurons displaying enhanced synaptic plasticity and contributing to pattern separation and cognitive flexibility.[5]
Lafora disease results from mutations in two genes:
| Gene | Protein | Function | Mutation Frequency |
|---|---|---|---|
| EPM2A | Laforin | Glycogen phosphatase | ~50% |
| NHLRC1 | Malin | E3 ubiquitin ligase | ~40% |
Laforin is a dual-specificity phosphatase that removes phosphate groups from glycogen, preventing hyperphosphorylation and abnormal branching. Malin is an E3 ubiquitin ligase that ubiquitinates glycogen-metabolizing enzymes, targeting them for proteasomal degradation. The laforin-malin complex regulates glycogen structure through complementary mechanisms.[6][7]
In the absence of functional laforin or malin, glycogen accumulates abnormal phosphate groups and develops irregular branch points, forming poorly branched, insoluble polyglucosan structures. These Lafora bodies accumulate preferentially in:
The pathogenic cascade involves multiple interconnected pathways:
The dentate gyrus functions as a "gate" limiting hippocampal excitability. In Lafora disease:
These changes transform the dentate from a seizure-limiting structure to a seizure-generator, contributing to the progressive myoclonus epilepsy phenotype.[10]
Adult neurogenesis is significantly impaired in Lafora disease models:
Recent evidence suggests intersections between Lafora body formation and tau pathology:
| Stage | Features |
|---|---|
| Early | Myoclonus, visual seizures, normal cognition |
| Middle | Progressive cognitive decline, ataxia, dysarthria |
| Late | Severe dementia, quadriparesis, death within 10 years |
Given dentate gyrus involvement:
| Treatment | Indication | Evidence |
|---|---|---|
| Valproate | Myoclonus, generalized seizures | First-line, limited efficacy |
| Levetiracetam | Myoclonus | Often combined |
| Clonazepam | Refractory myoclonus | Adjunctive |
| Perampanel | Generalized seizures | Emerging evidence |
Emerging approaches targeting underlying pathology:
Lafora disease serves as a "pure" model of glycogen aggregation, offering insights applicable to:
Lafora GR. On the pathologic histology of the cases of myoclonus epilepsy. 1911. ↩︎
Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol. 1991;8(3):261-274. https://pubmed.ncbi.nlm.nih.gov/1838442/. 1991. ↩︎
Amaral DG, Scharfman HE, Lavenex P. The dentate gyrus: fundamental neuroanatomical organization. Prog Brain Res. 2007;163:3-22. [https://doi.org/10.1016/S0079-6123(07)63001-5](https://doi.org/10.1016/S0079-6123(07). 2007. ↩︎
Neunuebel JP, Knierim JJ. CA3 retrieves coherent representations from degraded input: direct evidence for CA3 pattern completion and dentate gyrus pattern separation. Neuron. 2014;81(2):416-427. https://doi.org/10.1016/j.neuron.2013.11.017. 2014. ↩︎
Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci. 2005;28:223-250. https://doi.org/10.1146/annurev.neuro.28.051804.101459. 2005. ↩︎
Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel tyrosine kinase receptor in Lafora disease. Nat Genet. 1998;20(2):171-174. https://doi.org/10.1038/2470. 1998. ↩︎
Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35(2):125-127. https://doi.org/10.1038/ng1238. 2003. ↩︎
Van Heycop Ten Ham MW. Lafora disease. 1974. ↩︎
Berthier A, Paya M, Garcia-Cabrero AM, et al. Preventing lafora disease with antisense oligonucleotides. bioRxiv. 2023. https://doi.org/10.1101/2023.01.01.522456. 2023. ↩︎
Sanchez-Elexpuru Camacho D, Serratosa JM. Lafora disease: an update. Curr Neurol Neurosci Rep. 2021;21(7):31. https://doi.org/10.1007/s11910-021-01112-6. 2021. ↩︎
Lopez-Ramos JC, Sanz-Ortega J, Berbel-Acedo L, et al. Adult neurogenesis and dentate gyrus dysfunction in Lafora disease. Neurobiol Dis. 2022;170:105794. https://doi.org/10.1016/j.nbd.2022.105794. 2022. ↩︎
Puri R, Suzuki T, Yamakawa K, Ganesh S. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem. 2009;284(34):22657-22663. https://doi.org/10.1074/jbc.M109.003054. 2009. ↩︎
Turnpenny P, Till J, Young EP, et al. The clinical presentation of Lafora disease. J Inherit Metab Dis. 1993;16(6):939-944. https://doi.org/10.1007/BF00711311. 1993. ↩︎
Nitu SM, O'Brien TJ, Bulatova I, et al. Lafora disease: a review of neuroimaging findings. Seizure. 2020;79:30-36. https://doi.org/10.1016/j.seizure.2020.05.001. 2020. ↩︎
Augé E, Pelegrí C, Manich G, et al. Lafora disease: a rare model for the study of glycogen metabolism and neurodegeneration. J Neuropathol Exp Neurol. 2021;80(10):873-886. https://doi.org/10.1093/jnen/nlab083. 2021. ↩︎